| 6G5F: reference: Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models., Elliott M, Favre-Guilmard C, Liu SM, Maignel J, Masuyer G, Beard M, Boone C, Carre D, Kalinichev M, Lezmi S, Mir I, Nicoleau C, Palan S, Perier C, Raban E, Zhang S, Dong M, Stenmark P, Krupp J, Sci Adv. 2019 Jan 16;5(1):eaau7196. doi: 10.1126/sciadv.aau7196. eCollection 2019, Jan. PMID: 30746458 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).